Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATYRNASDAQ:CDTXNASDAQ:ITOSNASDAQ:NTGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATYRAtyr PHARMA$3.75-1.3%$3.24$1.42▼$4.66$333.77M0.79931,298 shs991,820 shsCDTXCidara Therapeutics$24.28-5.5%$20.72$10.14▼$28.42$304.64M0.8678,223 shs163,459 shsITOSiTeos Therapeutics$8.56-1.5%$6.72$4.80▼$18.13$332.60M1.39569,146 shs611,821 shsNTGNNeon Therapeutics$3.07$3.03$0.88▼$6.25$88.93M-0.81516,108 shsN/A2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATYRAtyr PHARMA-1.32%+14.68%+6.53%-13.19%+374,999,900.00%CDTXCidara Therapeutics-5.53%-4.78%+10.87%+13.09%+96.76%ITOSiTeos Therapeutics-1.50%+9.60%+19.72%+15.52%-52.07%NTGNNeon Therapeutics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATYRAtyr PHARMA2.662 of 5 stars3.61.00.00.03.23.30.6CDTXCidara Therapeutics4.3856 of 5 stars4.64.00.04.62.10.80.0ITOSiTeos Therapeutics3.1822 of 5 stars4.21.00.00.03.33.30.6NTGNNeon TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATYRAtyr PHARMA 3.14Buy$18.60396.00% UpsideCDTXCidara Therapeutics 3.22Buy$41.8672.39% UpsideITOSiTeos Therapeutics 2.43Hold$17.86108.61% UpsideNTGNNeon Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest NTGN, CDTX, ITOS, and ATYR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/23/2025CDTXCidara TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$31.00 ➝ $35.005/23/2025CDTXCidara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.005/19/2025ATYRAtyr PHARMAHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.00 ➝ $35.005/16/2025CDTXCidara TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$35.00 ➝ $50.005/14/2025ITOSiTeos TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$16.00 ➝ $13.005/14/2025ITOSiTeos TherapeuticsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$12.005/14/2025ITOSiTeos TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$16.00 ➝ $12.005/14/2025ITOSiTeos TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/14/2025ITOSiTeos TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral5/14/2025ITOSiTeos TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$47.00 ➝ $9.005/13/2025ITOSiTeos TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$15.00 ➝ $8.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATYRAtyr PHARMA$235K1,420.28N/AN/A$1.54 per share2.44CDTXCidara Therapeutics$302K1,008.75N/AN/A($1.82) per share-13.34ITOSiTeos Therapeutics$35M9.36N/AN/A$16.08 per share0.53NTGNNeon TherapeuticsN/AN/AN/AN/A$0.50 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATYRAtyr PHARMA-$50.39M-$0.81N/AN/AN/AN/A-79.44%-59.16%8/12/2025 (Estimated)CDTXCidara Therapeutics-$22.93M-$29.47N/AN/AN/A-289.05%-69.64%-33.73%8/11/2025 (Estimated)ITOSiTeos Therapeutics-$112.64M-$3.04N/AN/AN/AN/A-20.11%-17.50%N/ANTGNNeon Therapeutics-$79.78M-$2.86N/AN/AN/AN/A-199.09%-137.14%N/ALatest NTGN, CDTX, ITOS, and ATYR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025CDTXCidara Therapeutics-$5.45-$1.66+$3.79-$1.66N/AN/A5/7/2025Q1 2025ATYRAtyr PHARMA-$0.19-$0.17+$0.02-$0.17N/AN/A4/28/2025Q1 2025ITOSiTeos Therapeutics-$0.94-$0.80+$0.14-$0.80$9.35 millionN/A3/13/2025Q4 2024ATYRAtyr PHARMA-$0.23-$0.18+$0.05-$0.18$0.02 millionN/A3/6/2025Q4 2024CDTXCidara Therapeutics-$5.28-$5.38-$0.10-$5.37N/AN/A3/5/2025Q4 2024ITOSiTeos Therapeutics-$1.14-$1.01+$0.13-$1.01N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATYRAtyr PHARMAN/AN/AN/AN/AN/ACDTXCidara TherapeuticsN/AN/AN/AN/AN/AITOSiTeos TherapeuticsN/AN/AN/AN/AN/ANTGNNeon TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATYRAtyr PHARMA0.025.415.41CDTXCidara TherapeuticsN/A3.543.54ITOSiTeos TherapeuticsN/A14.8014.80NTGNNeon Therapeutics0.431.583.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATYRAtyr PHARMA61.72%CDTXCidara Therapeutics35.82%ITOSiTeos Therapeutics97.16%NTGNNeon Therapeutics54.71%Insider OwnershipCompanyInsider OwnershipATYRAtyr PHARMA3.70%CDTXCidara Therapeutics3.89%ITOSiTeos Therapeutics12.50%NTGNNeon Therapeutics38.93%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATYRAtyr PHARMA5389.00 million80.84 millionOptionableCDTXCidara Therapeutics9012.55 million6.51 millionNo DataITOSiTeos Therapeutics9038.27 million31.97 millionOptionableNTGNNeon Therapeutics10228.97 millionN/ANot OptionableNTGN, CDTX, ITOS, and ATYR HeadlinesRecent News About These CompaniesNeon Gold Records, Avenue A unite to launch Futures Music GroupOctober 24, 2024 | musicbusinessworldwide.comBioNTech grows in cell therapies, buying Kite's TCR platformSeptember 1, 2024 | pharmaphorum.comNeon Trap DefenseApril 14, 2024 | kotaku.comBCYC Bicycle Therapeutics plcApril 9, 2024 | seekingalpha.comneon oscillatorMarch 20, 2024 | hackaday.comNTGN_old Historical DataFebruary 20, 2024 | investing.com2000 Plymouth NeonJanuary 13, 2024 | cars.comNBCO Neon Bloom, Inc.December 22, 2023 | seekingalpha.comKansas City Ferris wheel could be out-dazzled by what will soon lie below: Neon AlleyNovember 13, 2023 | kansascity.comStarfield Neon shops and locations – every vendor in NeonNovember 4, 2023 | videogamer.comA Nixie Clock With Neon Bulb LogicOctober 5, 2023 | hackaday.comStarfield | Where To Get Neon (Ne)September 29, 2023 | hardcoregamer.comStarfield Neon City guide – everything you need to knowSeptember 14, 2023 | videogamer.comStarfield: All Shops in Neon CitySeptember 10, 2023 | twinfinite.netShadows in NeonSeptember 9, 2023 | ign.comStarfield Neon city guideAugust 19, 2023 | pcgamesn.comApex Legends Neon Network Collection EventAugust 4, 2023 | ign.comFab Five: Neon fashion finds to brighten up your summer wardrobeAugust 1, 2023 | vancouversun.comNeon White physical edition for PS5, Switch launches September 15July 21, 2023 | gematsu.comFast-paced platformer 'Neon White' is coming to XboxJune 22, 2023 | engadget.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNTGN, CDTX, ITOS, and ATYR Company DescriptionsAtyr PHARMA NASDAQ:ATYR$3.75 -0.05 (-1.32%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$3.82 +0.08 (+2.00%) As of 05/23/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.Cidara Therapeutics NASDAQ:CDTX$24.28 -1.42 (-5.53%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$24.35 +0.07 (+0.29%) As of 05/23/2025 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.iTeos Therapeutics NASDAQ:ITOS$8.56 -0.13 (-1.50%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$8.55 -0.01 (-0.11%) As of 05/23/2025 06:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.Neon Therapeutics NASDAQ:NTGNNeon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
